Kathryn Wildy
Rheumatology · Omaha, NENPI 1265543359
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 213 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Amgen at 35.9% of the total. Reporting peaked in 2019 at $1,286 and has fallen 98.8% since, to $16 in 2025.
Across 213 payments — averaging $14.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Aurinia Pharma U.S., Inc.$385
- AbbVie$293
- Bristol Myers Squibb$255
- Pfizer$243
- Johnson & Johnson$120
- plus $657 from 12 others
What the payments were for
- Food & beverage$3,00499%
- Education$431%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 84 | $1,094 |
| Aurinia Pharma U.S., Inc. | 24 | $385 |
| AbbVie | 15 | $293 |
| Bristol Myers Squibb | 22 | $255 |
| Pfizer | 19 | $243 |
| Johnson & Johnson | 8 | $120 |
| Novartis | 6 | $107 |
| UCB, Inc. | 6 | $97 |
| Genentech USA, Inc. | 5 | $85 |
| E.r. Squibb & Sons, L.L.C. | 5 | $78 |
| GSK | 6 | $77 |
| Boehringer Ingelheim | 4 | $61 |
| Lilly USA, LLC | 3 | $56 |
| Mallinckrodt Enterprises LLC | 2 | $35 |
| United Therapeutics Corporation | 1 | $22 |
| ANI Pharmaceuticals, Inc. | 1 | $16 |
| Radius Health, Inc. | 1 | $12 |
| Merck | 1 | $12 |
How this compares
$3,047 in reported general payments places this provider in the 65th percentile of 39 rheumatology providers in Nebraska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 28 | $305,767 |
| Taltz AutoinjectorIxekizumab | 11 | $76,578 |
| Hydroxychloroquine Sulfate | 267 | $9,646 |
| MethotrexateMethotrexate Sodium | 148 | $5,095 |
| Leflunomide | 63 | $2,869 |
| Cevimeline Hcl | 19 | $2,309 |
| Sulfasalazine DrSulfasalazine | 41 | $1,909 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 66 | $1,809 |
| Prednisone | 304 | $1,500 |
| Gabapentin | 86 | $1,396 |
| Celecoxib | 45 | $1,242 |
| Itraconazole | 12 | $952 |
| Cyclobenzaprine Hcl | 81 | $849 |
| Leucovorin Calcium | 37 | $517 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 17 | $483 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Omaha
- Abhijeet DanveOmaha$118K
- Jay KenikOmaha$69K
- Lynell KlassenOmaha$68K
- William PalmerOmaha$24K
- Ted MikulsOmaha$23K
- Amandeep RakhraOmaha$12K
- Carolyn CoyleOmaha$6K
- Joseph NahasOmaha$6K
- James OdellOmaha$4K
- Harry KleinOmaha$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.